Haim Pharma Group · raw details

Haim Pharma Group (HPG) is an Israel-based virtual drug development company, advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases. The company’s lead focus is amyotrophic lateral sclerosis (ALS), with a parallel program in Parkinson’s disease (PD).

HPG is pioneering an oral enteric-coated psilocin capsule Neurosilin designed for stability and controlled release. A U.S. provisional patent filed in 2025 protects the novel approach to treating neurodegenerative diseases.

The therapeutic concept is based on chronic, sub-hallucinogenic dosing, leveraging psilocin’s multimodal mechanisms: serotonin receptor engagement, restoration of glutamatergic balance, neuroplasticity enhancement, mitochondrial protection, and attenuation of neuroinflammation. Together, these actions aim to slow disease progression and stabilize neuronal viability in ALS and PD.

HPG has taken a proactive regulatory path, engaging with the FDA and submitting a briefing package in July 2025, outlining its development strategy and clinical roadmap.

The company operates through a virtual model, coordinating with global CROs, CDMOs, and academic partners. Its work is guided by experienced clinical and development advisors with deep expertise in neurology, biostatistics, and regulatory strategy.

Haim Pharma group is supported by key knowledge leaders in the area of ALS and clinical trials and is committed to redefining the treatment paradigm for ALS leverage psilocin as a personalized, disease-modifying therapy.